How would you decide on VRd vs DRd for initial management of transplant ineligible multiple myeloma?  

Are there specific patient groups where you would choose one over the other?

Are the cost differences significant enough to dissuade you from choosing one over another?



Answer from: Medical Oncologist at Academic Institution